Oncolytics Biotech Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on February 5, 2007, provides unaudited financial information for Oncolytics Biotech Inc., a Canadian biotechnology company. The financial data presented covers the nine-month and three-month periods ended September 30, 2006, along with cumulative figures from inception (April 2, 1998) to September 30, 2006. The filing primarily details the reconciliation of financial statements from Canadian GAAP to US GAAP.
Key Financial Metrics (US GAAP)
| Metric | 9 Months Ended Sep 30, 2006 | 3 Months Ended Sep 30, 2006 | Cumulative to Sep 30, 2006 |
|---|---|---|---|
| Net Loss | $9,136,294 | $3,334,794 | $58,634,086 |
| Loss Per Share (Basic & Diluted) | $(0.25) | $(0.09) | N/A |
| Intellectual Property (Balance Sheet) | $4,069,140 | N/A | N/A |
| Deficit (Accumulated) | $58,634,086 | N/A | N/A |
Cash Flow: The filing states there are no differences between Canadian GAAP and US GAAP regarding cash flows from operating, financing, or investing activities. Specific cash flow values are not provided in this excerpt.
Debt and Liquidity: The provided text does not contain specific data on debt levels, cash balances, or liquidity ratios.
Material Changes and GAAP Reconciliation
The primary material change disclosed is the adjustment required to convert Canadian GAAP figures to US GAAP. The reconciliation involves:
- Amortization of Intellectual Property: A reduction of $271,125 for the nine-month period and $90,375 for the three-month period to align with US GAAP.
- Future Income Tax Recovery: A cumulative adjustment of $1,115,000 recognized under US GAAP.
- Push-Down Accounting: Under US GAAP, $2,500,000 of intellectual property recorded during the 1999 acquisition of the company by SYNSORB is not capitalized. Consequently, related amortization, tax recoveries, and contributed surplus amounts recorded under Canadian GAAP were reversed for US GAAP reporting.
Guidance, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the accounting adjustments noted. The document serves strictly as a disclosure of financial statement reconciliations required for US reporting.
Investor Verification Checklist
- Verify the full cash flow statement to assess liquidity, as specific cash balance figures are absent from this excerpt.
- Confirm the status of the $2,500,000 intellectual property asset and its treatment in future US GAAP filings.
- Review the full balance sheet to determine current debt obligations and working capital position.
- Check for subsequent filings regarding the company's operational progress, as this document focuses solely on historical accounting adjustments.